Dr. Michael Abramoff Invited to Participate in a Federal Trade Commission Hearing on Ethical and Consumer Protection Issues Related to Real-World Ai Applications
The Federal Trade Commission is holding a public hearing on ethical and consumer protection issues related to new artificial intelligence (AI) applications. IDx Founder and CEO, Michael D. Abramoff, MD, PhD, will share his expertise on the safe implementation of AI in healthcare.
The hearing comes at a time when rapid expansion of AI applications is raising challenging questions on the impact these new technologies will have on consumers. Healthcare is an industry that has seen tremendous growth in AI technologies and AI in healthcare spending is projected to surpass $34 billion by 2025. Healthcare is also an industry where ethical concerns weigh heavily on the minds of experts and policymakers.
“Not all AI is created equal, and we need to educate the public on how to assess different types of healthcare applications,” said Abramoff. “It is critical that autonomous AI applications are thoroughly validated and developed in a clinically safe and explainable way that builds trust with patients and clinicians. Safety needs to be the number one concern for responsible AI companies.”
Abramoff will lend his expertise as a practicing physician and the founder of the first company to receive FDA clearancefor an autonomous AI diagnostic system during a section of the hearing entitled, “Understanding Algorithms, Artificial Intelligence, and Predictive Analytics Through Real-World Applications.” He has previously provided his expertise on AI in healthcare to the U.S. Congress and the White House Office of Science and Technology.
To date, IDx is the only the company to develop and implement autonomous AI in real-world clinical care. The company received FDA clearance in April 2018 for IDx-DR, an AI system that detects diabetic retinopathy without requiring a clinician to interpret the image or results. This enables health care providers who are not normally involved in eye care to use the AI system to test for this leading cause of blindness during routine office visits.